CARB-X is funding Spanish biotech Vaxdyn to develop a new vaccine to prevent superbug infections that cause life-threatening pneumonia and other deadly infections

Vaxdyn’s new vaccine against Gram-negative pathogens, if approved, would help curb the rising threat of drug resistant bacteria (BOSTON) - CARB-X is awarding Vaxdyn, based in Seville, Spain, up to US$892,000, plus an additional $6.36 million if certain project milestones are met, to develop a new vaccine to prevent life-threatening drug-resistant infections, including pneumonia. Vaxdyn